Latest Trials
Latest News
FAQ
Pharmaceutical Companies
Pharma Details
Janssen-Cilag Ltd.
🇬🇧
United Kingdom
Country
🇬🇧
United Kingdom
Ownership
Subsidiary
Employees
-
Market Cap
-
Website
http://www.janssen.com
Clinical Trials
Related News
A Study to Assess the Rate of Hospitalization in Participants With Schizophrenia Treated With Antipsychotics
Completed
Conditions
Schizophrenia
Subscribe
First Posted Date
2016-03-18
Last Posted Date
2016-05-24
Lead Sponsor
Janssen-Cilag Ltd.
Target Recruit Count
310
Registration Number
NCT02712463
Subscribe
An Observational/Non-interventional, Study of NS3/4a Protease and NS5A Protein of Hepatitis C Virus in Brazilian Participants With Chronic HCV Infection
Completed
Conditions
Hepatitis C Virus
Subscribe
First Posted Date
2015-11-05
Last Posted Date
2017-02-06
Lead Sponsor
Janssen-Cilag Ltd.
Target Recruit Count
239
Registration Number
NCT02597270
Subscribe
Observational Study in Participants With Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM) and Non-Hodgkin's Lymphoma (NHL) in Latin America
Completed
Conditions
Leukemia
Non-Hodgkin
Multiple Myeloma
Lymphoid
Lymphoma
Interventions
Other: Multiple Myeloma (MM)
Other: Non-Hodgkin's lymphoma (NHL)
Other: Chronic Lymphocytic Leukemia (CLL)
Subscribe
First Posted Date
2015-09-24
Last Posted Date
2016-07-20
Lead Sponsor
Janssen-Cilag Ltd.
Target Recruit Count
5443
Registration Number
NCT02559583
Subscribe
Study to Evaluate Efficacy and Safety of a Double Treatment Plan Using a Combination of Mebendazole and Quinfamide for Treating Intestinal Helminthiasis and Amebiasis in the Mexican Population
Phase 4
Completed
Conditions
Helminthiasis
Amoebiasis
Interventions
Drug: Mebendazole
Drug: Quinfamide
Drug: Placebo
Subscribe
First Posted Date
2015-03-11
Last Posted Date
2015-04-14
Lead Sponsor
Janssen-Cilag Ltd.
Target Recruit Count
100
Registration Number
NCT02385058
Subscribe
An Efficacy and Safety Study of Risperidone Long-Acting Microspheres in Participants With Schizophrenia, Schizophreniform or Schizoaffective Disorders
Phase 4
Completed
Conditions
Schizophrenia
Schizophreniform Disorder
Schizoaffective Disorder
Interventions
Drug: Risperidone
Subscribe
First Posted Date
2013-05-16
Last Posted Date
2013-08-14
Lead Sponsor
Janssen-Cilag Ltd.
Target Recruit Count
80
Registration Number
NCT01855074
Subscribe
A Study of Prophylaxis for Migraine Patients With Topiramate in India
Completed
Conditions
Migraine
Interventions
Drug: No intervention
Subscribe
First Posted Date
2013-04-22
Last Posted Date
2013-04-22
Lead Sponsor
Janssen-Cilag Ltd.
Target Recruit Count
209
Registration Number
NCT01836874
Subscribe
Switching From Oral Antipsychotics to Long-Acting Risperidone in Participants With Schizophrenia
Phase 4
Completed
Conditions
Schizophrenia
Interventions
Drug: Risperidone prolonged release
Subscribe
First Posted Date
2012-11-14
Last Posted Date
2014-04-29
Lead Sponsor
Janssen-Cilag Ltd.
Target Recruit Count
53
Registration Number
NCT01726335
Subscribe
Early Access to Low-dose Ritonavir (TMC114/r) and Other Antiretrovirals (ARVs) for Treatment-naive or Early Treatment Experienced in HIV-1 Patients
Phase 4
Completed
Conditions
HIV-1
Interventions
Drug: TMC114/ritonavir
Subscribe
First Posted Date
2012-10-05
Last Posted Date
2016-05-23
Lead Sponsor
Janssen-Cilag Ltd.
Target Recruit Count
10
Registration Number
NCT01702090
Subscribe
An Efficacy and Safety Study of Low-dose Transdermal Therapeutic System (TTS)-Fentanyl D-Trans in Taiwan Participants With Cancer Pain
Phase 4
Completed
Conditions
Cancer, Pain
Interventions
Drug: Transdermal Therapeutic System (TTS)-Fentanyl
Subscribe
First Posted Date
2008-10-13
Last Posted Date
2014-09-17
Lead Sponsor
Janssen-Cilag Ltd.
Target Recruit Count
14
Registration Number
NCT00771199
Subscribe
An Efficacy and Safety Study to Compare Fentanyl Ionsys and Routine Care With Intravenous (IV) Morphine Patient-controlled Analgesia (PCA) in Participants Who Have Undergone Elective Major Abdominal or Orthopedic Surgery
Phase 4
Terminated
Conditions
Pain, Postoperative
Interventions
Device: Fentanyl IONSYS
Device: Morphine IV PCA
Subscribe
First Posted Date
2008-10-06
Last Posted Date
2013-04-25
Lead Sponsor
Janssen-Cilag Ltd.
Target Recruit Count
108
Registration Number
NCT00766506
Subscribe
Prev
1
2
3
4
Next
© Copyright 2024. All Rights Reserved by MedPath
Home
Terms & Conditions
Privacy Policy